Beverly Hills MD Celebrates Its 10th Anniversary
An Innovative Line of Professional Cosmeceutical Formulas Designed To Help People “Rewind Time” on their Skin BEVERLY HILLS, Calif., June 1, 2024 /PRNewswire/ — Beverly Hills MD®, the cutting-edge skincare line created by renowned plastic surgeons Dr. John Layke and Dr. Payman Dan
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development INDIANAPOLIS, June 1, 2024 /P
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
BOSTON, June 1, 2024 /PRNewswire/ — Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by alpaca IGH-VDJ genes in-situ. In 1993, naturally occ
James Avery Artisan Jewelry Opens New Store at Westover Marketplace
KERRVILLE, Texas, June 1, 2024 /PRNewswire/ — James Avery Artisan Jewelry, a family-owned jewelry retailer based in Texas, is excited to announce the opening of its new store at Westover Marketplace in San Antonio. The new store is located at 8219 State Highway 151, Suite 128, San Antonio, TX
Boehringer Ingelheim’s COPD and asthma inhalers are now available for $35 a month for eligible patients
Boehringer’s first-of-its-kind program automatically reduces the costs of its COPD and asthma inhalers at the pharmacy counter for vast majority of eligible patientsProgram provides predictable, affordable and consistent costs for as many patients as possible, including uninsured patients and
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218 plus Keytruda combination therapy in patients with advanced solid tumorsA 40% overall response rate (ORR) and 100% disease control rate (DCR) were achieved in high-dose cohort (195 mg/day)TU2218 was well
CMA reflects on National Indigenous History Month
OTTAWA, ON, June 1, 2024 /CNW/ – The Canadian Medical Association (CMA) is pleased to join people across the country in recognizing National Indigenous History Month. As we reflect on the rich history, resilience, diverse cultures and achievements of First Nations, Inuit and Métis Peoples, we
BALEAF & SOJOS to host “Summer it up” summer fashion extravaganza!
NEW YORK, June 1, 2024 /PRNewswire/ — Leading fashion brands baleaf and SOJOS are teaming up to present a spectacular summer fashion event, Summer it up set to take place this June in Chicago. More than just a fashion show, this event aims to empower individuals to define their unique style f
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors With approximately two years of median follow-up, as of July 28, 2023, median duration of res
/R E M I N D E R — Media Advisory – Prime Minister’s itinerary for Saturday, June 1, 2024/
OTTAWA, ON, May 31, 2024 /CNW/ – Note: All times local National Capital Region, Canada No public events scheduled This document is also available at https://pm.gc.ca SOURCE Prime Minister’s Office
